生物学时代性结肠炎的手术治疗趋势 - - 一项基于人口的研究,使用德国诊断相关群体数据
Maximilian Berlet1, Kamacay Cira1, Alissa Jell1
1Department of Surgery, TUM University Hospital, Klinikum rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
Surgery
|July 1, 2025
概括
性结肠炎 (UC) 的生物疗法已经进步,但结肠切除和直肠切除率保持不变. 最少侵入性手术增加,与开放手术相比,并发症率较低.
科学领域:
- 胃肠病学 胃肠病学
- 手术瘤学手术瘤学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 生物疗法已经在性结肠炎 (UC) 治疗中取得了先进的进展.
- 生物制剂对UC手术率和并发症的影响尚不清楚.
- 在先进治疗时代的外科趋势和结果需要分析.
研究的目的:
- 分析2008-2018年间性结肠炎手术的趋势和病例数.
- 在此期间评估UC手术技术的变化.
- 评估与UC手术相关的并发症率.
主要方法:
- 基于德国全国医院出院数据 (2008-2018) 的基于人口的分析.
- 包括所有被诊断患有性结肠炎的住院患者 (ICD-10代码K51.0-K51.9).
- 来自德国联邦药物和医疗器械研究所的生物制品市场数据的检查.
主要成果:
- 分析了超过522,000个UC病例;生物制剂市场显著扩大.
- 部分结肠切除率下降;大肠切除和直肠切除率增加或保持稳定.
- 微创手术的采用率从14.5%上升到65.6%,转化率和并发症率降低.
结论:
- 尽管生物可用性增加,但UC的结肠切除和直肠切除率并没有下降.
- 最少侵入性手术的使用越来越多,并且与更好的结果有关.
- 需要进一步的研究,以了解先进的UC疗法的长期外科影响.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Inflammatory Bowel Disease V: Surgical Management
224
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
224
Drugs for Treatment of Ulcerative Colitis in IBD
243
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
243
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
430
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
430
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
239
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
239
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
277
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
277


